Areas of Interest & Competitive Research Grants - 博彩app软件下载app软件下载 Myers 博彩app软件下载

Areas of Interest (AOI)

博彩app软件下载app软件下载 Myers 博彩app软件下载 seeks Independent Research applications across all therapeutic areas.  Our Areas of Interest outline additional criteria to help guide the scientific community.  All concept applications submitted that best align with our interests will be considered and evaluated. Concepts may be submitted outside of the posted AOIs, but the threshold for approval may be relatively high.

Therapeutic Area and / or Asset AOIs Posted on BMS.com Pre-Concept Submission Period
Start Date End date
Hematology 23-Nov-20 18-Jan-21 5-Feb-21
Immunology – ZEPOSIA® (ozanimod) Multiple Sclerosis 23-Nov-20 4-Jan-21 22-Jan-21
Immunology – ZEPOSIA® (ozanimod) Ulcerative colitis 2-Dec-20 4-Jan-21 29-Jan-21
Immunology - ORENCIA® (abatacept) 9-Dec-20 18-Jan-21 5-Feb-21
Oncology 15-Feb- 21 29-Mar-21 23-Apr-21

 


Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.


  • If you are a potential investigator who is interested in seeking support to conduct independent research involving  Nivolumab  in Japan, Taiwan, or Korea, click here
  • If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
  • If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
  • If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here
  • If you are a potential investigator who is interested in seeking support for independent research involving idecabtagene vicleucel or lisocabtagene maraleucel, click here
  • If you are a potential investigator who is interested in seeking support for independent research involving NKTR-214 (Bempegaldesleukin) & Nivolumab, click here
     
    Nivolumab + Bempegaldesleukin – Clinical and Non Clinical Research proposals will be accepted from January 15, 2021 to March 15, 2021
     
    Nivolumab + Bempegaldesleukin - Areas of Interest include:
    • Translational studies (Contribution of component, Mechanism of Action, biomarkers of response)
    • Melanoma, RCC, Urothelial clinical studies (ie: expanded patient populations)(includes all settings of disease)
    • Real World Data or Data investigating endpoints or surrogates of response/survival

Please click on the product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including Boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.


Begin a New Application
If interested in a product or an investigational compound not listed
我是混淆代码

如果您的浏览器未跳转,请点击此处进行游戏并领取优惠

技术支持 AI智能站群 luis888.vip@gmail.com